PharmTech AI Pulse Check panelists explain why attribution, audit trails, and sign-off matter more than AI watermark detection for GxP quality teams.
News|Articles|November 2, 2015
Pierre Fabre Joins IQ Consortium
Author(s)Pharmaceutical Technology Editors
The IQ Consortium is an organization that brings together pharma and biotech companies and facilitates partnerships between members.
Advertisement
Pierre Fabre Medicament announced that it has joined the International Consortium for Innovation and Quality in Pharmaceutical Development (IQ), a scientific non-profit organization bringing together 39 pharmaceutical and biotechnology companies from around the world. The aim of the consortium is to facilitate scientific and technological partnerships among its members and enable relationships to be built with international regulatory authorities such as FDA and EMA.
Being a part of the IQ Consortium's network will allow Pierre Fabre Medicament to prepare for scientific and regulatory changes in the R&D field, and to implement and shape R&D best practices, while benefitting from the experience of other members.
Pierre Fabre's research teams will participate in many of the Consortium's committees, including those specializing in "clinical pharmacology," "drug metabolism," "drug safety," "antibody-drug conjugates," "3Rs-alternative methods," "pharmacokinetics and pharmacodynamics," and "tissue distribution imaging."
As a member of the IQ Consortium, the Pierre Fabre Group also intends to build relationships with university and public research institutes worldwide, and to expand its international network.
Source:
Advertisement
Related to this article
Ron Scarboro, Azurity Pharmaceuticals, explains how cross-functional development, disciplined reformulation, and post-approval metrics can help proven medicines work in everyday use.
The FDA approves oral pritelivir for drug-resistant herpes sores in immunocompromised patients; what it means for antiviral development and manufacturing.
This week, drug formulation and manufacturing experts showcased their knowledge, and companies exhibited their products, at CPHI Milan.
FDA approves Teva’s Weltruza, a once-monthly subcutaneous olanzapine for schizophrenia whose copolymer depot eliminates post-injection monitoring.
Equivalence test using two one-sided tests are widely used for demonstrating the comparability of treatment effects in different research fields. The method described in the manuscript aims to use simulations in Microsoft Excel to compute power for 2 one-sided tests for two groups with unequal variances.
Richard Jaenisch examines whether FDA's NAM pathway truly shortens drug pipelines or just shifts the evidentiary burden elsewhere.
Susan J. Schniepp, distinguished fellow with Nelson Labs, and Siegfried Schmitt, PhD, vice president, Technical, with Parexel, clear up some of the confusion about what does and does not need to be complied with regarding standards set by international pharmacopoeias.
Advertisement
Advertisement